Recipient screening in IVF: First data from women undergoing anonymous oocyte donation in Dublin

Hdl Handle:
http://hdl.handle.net/10147/132563
Title:
Recipient screening in IVF: First data from women undergoing anonymous oocyte donation in Dublin
Authors:
Walsh, Anthony PH; Omar, Ahmed B; Marron, Kevin D; Walsh, David J; Salma, Umme; Sills, E. Scott
Citation:
Reproductive Health. 2011 Apr 20;8(1):8
Issue Date:
20-Apr-2011
URI:
http://hdl.handle.net/10147/132563
Abstract:
Abstract Background Guidelines for safe gamete donation have emphasised donor screening, although none exist specifically for testing oocyte recipients. Pre-treatment assessment of anonymous donor oocyte IVF treatment in Ireland must comply with the European Union Tissues and Cells Directive (Directive 2004/23/EC). To determine the effectiveness of this Directive when applied to anonymous oocyte recipients in IVF, we reviewed data derived from selected screening tests performed in this clinical setting. Methods Data from tests conducted at baseline for all women enrolling as recipients (n = 225) in the anonymous oocyte donor IVF programme at an urban IVF referral centre during a 24-month period were analysed. Patient age at programme entry and clinical pregnancy rate were also tabulated. All recipients had at least one prior negative test for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis performed by her GP or other primary care provider before reproductive endocrinology consultation. Results Mean (±SD) age for donor egg IVF recipients was 40.7 ± 4.2 yrs. No baseline positive chlamydia, gonorrhoea or syphilis screening results were identified among recipients for anonymous oocyte donation IVF during the assessment interval. Mean pregnancy rate (per embryo transfer) in this group was 50.5%. Conclusion When tests for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis already have been confirmed to be negative before starting the anonymous donor oocyte IVF sequence, additional (repeat) testing on the recipient contributes no new clinical information that would influence treatment in this setting. Patient safety does not appear to be enhanced by application of Directive 2004/23/EC to recipients of anonymous donor oocyte IVF treatment. Given the absence of evidence to quantify risk, this practice is difficult to justify when applied to this low-risk population.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorWalsh, Anthony PH-
dc.contributor.authorOmar, Ahmed B-
dc.contributor.authorMarron, Kevin D-
dc.contributor.authorWalsh, David J-
dc.contributor.authorSalma, Umme-
dc.contributor.authorSills, E. Scott-
dc.date.accessioned2011-06-03T15:19:24Z-
dc.date.available2011-06-03T15:19:24Z-
dc.date.issued2011-04-20-
dc.identifierhttp://dx.doi.org/10.1186/1742-4755-8-8-
dc.identifier.citationReproductive Health. 2011 Apr 20;8(1):8-
dc.identifier.urihttp://hdl.handle.net/10147/132563-
dc.description.abstractAbstract Background Guidelines for safe gamete donation have emphasised donor screening, although none exist specifically for testing oocyte recipients. Pre-treatment assessment of anonymous donor oocyte IVF treatment in Ireland must comply with the European Union Tissues and Cells Directive (Directive 2004/23/EC). To determine the effectiveness of this Directive when applied to anonymous oocyte recipients in IVF, we reviewed data derived from selected screening tests performed in this clinical setting. Methods Data from tests conducted at baseline for all women enrolling as recipients (n = 225) in the anonymous oocyte donor IVF programme at an urban IVF referral centre during a 24-month period were analysed. Patient age at programme entry and clinical pregnancy rate were also tabulated. All recipients had at least one prior negative test for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis performed by her GP or other primary care provider before reproductive endocrinology consultation. Results Mean (±SD) age for donor egg IVF recipients was 40.7 ± 4.2 yrs. No baseline positive chlamydia, gonorrhoea or syphilis screening results were identified among recipients for anonymous oocyte donation IVF during the assessment interval. Mean pregnancy rate (per embryo transfer) in this group was 50.5%. Conclusion When tests for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis already have been confirmed to be negative before starting the anonymous donor oocyte IVF sequence, additional (repeat) testing on the recipient contributes no new clinical information that would influence treatment in this setting. Patient safety does not appear to be enhanced by application of Directive 2004/23/EC to recipients of anonymous donor oocyte IVF treatment. Given the absence of evidence to quantify risk, this practice is difficult to justify when applied to this low-risk population.-
dc.titleRecipient screening in IVF: First data from women undergoing anonymous oocyte donation in Dublin-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderWalsh et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2011-06-03T15:04:24Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.